Despite this controversy, the strategy is being explored in more trials: NCT00393783 using the rat HER2, NCT00436254 employing the intracellular domain of HER2, and NCT03384914 comparing the efficacy of DNA vaccines to HER2-pulsed dendritic cell vaccines, all in HER2-positive breast cancer patients. Here, ERBB2 is linked to breast carcinoma.